Citi raises target for AstraZeneca stock to GBp 18,600

Published on 10/07/2026 at 10:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Citi sees USD 7.00 billion peak sales for tozorakimab. AstraZeneca stock costs EUR 141.35 on October 7, 2026 versus EUR 140.88, plus 0.33 percent.

Wissenschaftler im weißen Kittel arbeiten in modernem Pharma-Forschungslabor — AstraZeneca plc (ISIN GB0009895292) betreibt moderne Forschungslabore für pharmazeutische Wirkstoffentwicklung und klinische Studien weltweit, Illustration mit AI erstellt.

AstraZeneca (ISIN GB0009895292) was trading at EUR 141.35 at Lang & Schwarz on October 7, 2026 at 10:16 a.m. CEST, plus 0.33 percent versus the prior close of EUR 140.88. On October 6, 2026, Citi raised its target for AstraZeneca stock to GBp 18,600 from GBp 17,800 and retained a Buy rating, as reported by FMP.

Citi sees larger drug potential

Citi's revised view centers on AstraZeneca's late-stage pipeline. The broker lifted its peak sales forecast for tozorakimab to USD 7.00 billion and for SERENA-6 to USD 1.10 billion, while removing a USD 1.70 billion forecast for SERENA-4, according to FMP.

The change adds 4.00 percent to 5.00 percent to Citi's discounted cash flow valuation, the same report says. That calculation gives the target increase a measurable link to expected drug sales rather than to a broad sector call.

Clinical milestones set the next test

Citi identified the AVANZAR trial as the next major test and said a hazard ratio of 0.75 to 0.80 or better would matter for progression-free or overall survival, according to Yahoo Finance on October 6, 2026. The range describes a lower event risk for the treatment group, but it also leaves the investment case dependent on trial execution.

AstraZeneca's investor-relations page lists a Meet the Management event at ASBMR on October 12, 2026, with a 9M and Q3 2026 results section also highlighted, according to AstraZeneca.

Stock holds a measured daily gain

The Lang & Schwarz quote stood at EUR 141.35 on October 7, 2026 at 10:16 a.m. CEST, compared with the prior close of EUR 140.88. AstraZeneca's market capitalization was USD 246.0 billion as of October 6, 2026, while the LSE-listed ordinary shares carry the ticker AZN and belong to the FTSE 100. The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.